Ríos S E, Cho Y K, Miziorko H M
Biochemistry Department, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Biochim Biophys Acta. 2001 Apr 30;1531(3):165-8. doi: 10.1016/s1388-1981(01)00105-6.
The list of diseases linked to defects in lipid metabolism has recently been augmented by the addition of hyperimmunoglobulinemia D and periodic fever syndrome (HIDS: MIM 260920), which are correlated with depressed levels of mevalonate kinase activity [1,2] and protein [1]. More specifically, a V377I substitution has been proposed to account for this disease. We observed that V377 appears to be far from invariant in eukaryotic mevalonate kinases. Prokaryotic mevalonate kinases are lower in molecular weight and several terminate prior to residue 377 of the eukaryotic proteins. These observations prompted our direct test of the impact of V377 on activity and protein stability by engineering a V377I mutation in a recombinant human mevalonate kinase. The mutant protein has been isolated and kinetically characterized. In comparison with wild-type enzyme, V377I exhibits only modest differences (notably > or = 6-fold inflation of K(m(MVA))) that do not account for the diminished mevalonate kinase activity assayed in HIDS cell extracts. Moreover, thermal inactivation (50 degrees C) of isolated wild-type and V377I enzymes demonstrates little difference in stability between these proteins. We conclude that a single V377I substitution is unlikely to explain the observation of depressed mevalonate kinase stability and catalytic activity in HIDS.
与脂质代谢缺陷相关的疾病列表最近因高免疫球蛋白血症D和周期性发热综合征(HIDS:MIM 260920)的加入而有所增加,这些疾病与甲羟戊酸激酶活性[1,2]和蛋白[1]水平降低相关。更具体地说,有人提出V377I替代可解释这种疾病。我们观察到,在真核甲羟戊酸激酶中,V377似乎远非不变。原核甲羟戊酸激酶分子量较低,有几种在真核蛋白的377位残基之前就终止了。这些观察结果促使我们通过在重组人甲羟戊酸激酶中构建V377I突变来直接测试V377对活性和蛋白质稳定性的影响。已分离出突变蛋白并对其进行了动力学表征。与野生型酶相比,V377I仅表现出适度差异(显著的是K(m(MVA))增加了≥6倍),这并不能解释在HIDS细胞提取物中检测到的甲羟戊酸激酶活性降低。此外,分离的野生型和V377I酶的热失活(50℃)表明这些蛋白质之间的稳定性差异很小。我们得出结论,单一的V377I替代不太可能解释在HIDS中观察到的甲羟戊酸激酶稳定性和催化活性降低的现象。